Clene Q2 FY26 net loss widens 81% to $13.42 million - CLNN News | RalliesClene Q2 FY26 net loss widens 81% to $13.42 million
C
CLNN• Pipeline timing
- CNM-Au8 ALS NDA filing is targeted for early Q4 2026; Phase 3 RESTORE-ALS trial is planned to start in Q2 2027.
Q2 financial results
- Clene posted Q2 net loss of $13.42 million, widening 81% from a year earlier as total other expense rose to $8.08 million.
- Revenue climbed to $90,000; product revenue rose to $74,000 from minimal levels, while royalty revenue slipped 38% to $16,000.
- Operating loss narrowed 9% to $5.35 million as total operating expenses fell 8% to $5.44 million.
- Cash and cash equivalents increased to $9.7 million at June 30, 2026; net cash used in operating activities improved to $7.12 million.
NIMU
•
